Latest Advances

  • Condition: Thalassemia
  • Journal: Blood advances
  • Treatment Used: Luspatercept
  • Number of Patients: 336
  • Published —
The study researched the use of luspatercept for patients with thalassemia.
  • Condition: Sickle Cell Disease
  • Journal: Blood advances
  • Treatment Used: Allogeneic Stem Cell Transplantation with Omidubicel
  • Number of Patients: 13
  • Published —
This study tested the safety and efficacy of using allogeneic stem cell transplantation with omidubicel to treat patients with sickle cell disease.
  • Condition: Chronically Transfused Patients with Thalassemia
  • Journal: Immunohematology
  • Treatment Used: Antigen-Matched Red Blood Cell Units
  • Number of Patients: 24
  • Published —
This study determined the benefits of antigen matched transfusion guided by DNA-based typing in chronically transfused patients with thalassemia (blood disorder).
  • Condition: Sickle Cell Disease and Thalassemia
  • Journal: Blood advances
  • Treatment Used: Stem Cell Transplant or Gene Therapy
  • Number of Patients: 517
  • Published —
This systematic review evaluated the quality of life in patients with sickle cell disease (SCD) and thalassemia after treatment with hematopoietic stem cell transplant (HSCT) or gene therapy.
  • Condition: Thalassemia
  • Journal: PloS one
  • Treatment Used: Iron Reduction Therapy
  • Number of Patients: 149
  • Published —
This study tested the safety and efficacy of using iron reduction therapy to treat patients with thalassemia.
  • Condition: ?-Thalassemia Major
  • Journal: Hemoglobin
  • Treatment Used: Calcium Channel Blockers(CCBs) in Conjunction with Standard Iron-Chelating Agents
  • Number of Patients: 210
  • Published —
This review of the literature investigated d the clinical effectiveness of calcium channel blockers (CCBs) in conjunction with chelation therapy for reducing iron overload in patients with thalassemia (blood disorder).
  • Condition: Schizophrenia
  • Journal: Journal of clinical psychopharmacology
  • Treatment Used: Nanocurcumin
  • Number of Patients: 56
  • Published —
In this study, researchers evaluated the safety and effectiveness of nanocurcumin for the treatment of negative symptoms in patients with schizophrenia.
  • Condition: Sickle Cell Disease
  • Journal: The New England journal of medicine
  • Treatment Used: Post-Transcriptional Genetic Silencing of BCL11A
  • Number of Patients: 6
  • Published —
This study investigated the use of post-transcriptional genetic silencing of BCL11A in the treatment of patients with sickle cell disease.
  • Condition: Sickle Cell Disease (SCD) and ?-Thalassemia
  • Journal: The New England journal of medicine
  • Treatment Used: CRISPR-Cas9 Gene Editing
  • Number of Patients: 2
  • Published —
This case report describes the use of CRISPR-Cas9 gene editing in the treatment of patients with transfusion-dependent ?-thalassemia (TDT) and sickle cell disease (SCD).
  • Condition: Thalassemia
  • Journal: Hematology. American Society of Hematology. Education Program
  • Treatment Used: Chronic Transfusion
  • Number of Patients: 0
  • Published —
This article discusses issues concerning chronic transfusion in patients with thalassemia.
  • Condition: Osteonecrosis of the Femoral Head
  • Journal: Journal of biological regulators and homeostatic agents
  • Treatment Used: Total Hip Replacement
  • Number of Patients: 12
  • Published —
In this study, researchers evaluated the outcomes of undergoing total hip replacement for the treatment of osteonecrosis of the femoral head in patients with sickle cell disease.
  • Condition: Sickle Cell Disease
  • Journal: The Lancet. Haematology
  • Treatment Used: Hematopoietic Stem Cell Transplantation (HSCT)
  • Number of Patients: 0
  • Published —
This article discusses the role of hematopoietic stem cell transplantation (HSCT) for sickle cell disease in the era of targeted disease-modifying therapies and gene editing.
Showing 1-12 of 180